Tumor metabolic regulators: key drivers of metabolic reprogramming and the promising targets in cancer therapy

Kun Huang(Central South University), Changjing Cai(Central South University), Hong Shen(Nanfang Hospital), Shan Zeng(Central South University), Yihong Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Ying Han(Fujian University of Traditional Chinese Medicine)
Molecular Cancer
January 9, 2025
10.1186/s12943-024-02205-6
Cited by 98

Related Papers

Coexistence of Magnetic and Electric Orderings in the Metal–Formate Frameworks of [NH<sub>4</sub>][M(HCOO)<sub>3</sub>]
|Journal of the American Chemical Society|2011|484
In silico ADME and Toxicity Prediction of Ceftazidime and Its Impurities
|Frontiers in Pharmacology|2019|287
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
|The Lancet Haematology|2019|248
Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice
|Hepatology|2004|177
Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China
|Chinese Journal of Cancer Research|2019|126